BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19169185)

  • 21. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients.
    Prows CA; Nick TG; Saldaña SN; Pathak S; Liu C; Zhang K; Daniels ZS; Vinks AA; Glauser TA
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):385-94. PubMed ID: 19702490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles.
    Koopmans AB; Vinkers DJ; Gelan PJ; Hoek HW; van Harten PN
    Pharmacogenomics; 2017 Jul; 18(10):1003-1012. PubMed ID: 28639468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
    Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
    Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
    Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
    Yin SJ; Ni YB; Wang SM; Wang X; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2012 Jun; 37(3):364-9. PubMed ID: 21913948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
    Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
    J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping.
    Heller T; Kirchheiner J; Armstrong VW; Luthe H; Tzvetkov M; Brockmöller J; Oellerich M
    Ther Drug Monit; 2006 Oct; 28(5):673-7. PubMed ID: 17038884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
    Naujokaitis D; Asmoniene V; Kadusevicius E
    Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequencies of
    Scherf-Clavel M; Weber H; Unterecker S; Müller DJ; Deckert J
    World J Biol Psychiatry; 2024 Apr; 25(4):214-221. PubMed ID: 38493365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia.
    Roddam PL; Rollinson S; Kane E; Roman E; Moorman A; Cartwright R; Morgan GJ
    Pharmacogenetics; 2000 Oct; 10(7):605-15. PubMed ID: 11037802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
    Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
    Ford GA; Wood SM; Daly AK
    Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
    Serrano D; Lazzeroni M; Zambon CF; Macis D; Maisonneuve P; Johansson H; Guerrieri-Gonzaga A; Plebani M; Basso D; Gjerde J; Mellgren G; Rotmensz N; Decensi A; Bonanni B
    Pharmacogenomics J; 2011 Apr; 11(2):100-7. PubMed ID: 20309015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers.
    Tamminga WJ; Wemer J; Oosterhuis B; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 Dec; 57(10):717-22. PubMed ID: 11829201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.
    Salazar-Flores J; Torres-Reyes LA; Martínez-Cortés G; Rubi-Castellanos R; Sosa-Macías M; Muñoz-Valle JF; González-González C; Ramírez A; Román R; Méndez JL; Barrera A; Torres A; Medina R; Rangel-Villalobos H
    Genet Test Mol Biomarkers; 2012 Sep; 16(9):1098-104. PubMed ID: 22913530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
    Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
    Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.